Sven Zimmermann

Sven Zimmermann is an experienced executive in the biotechnology and pharmaceutical industries, currently serving as Chief Executive Officer at Inotrem since March 2021 and Board Member at Nanolive SA since December 2018. Previously, Sven held significant financial leadership roles, including Chief Financial Officer at MetrioPharm, Novimmune SA, Auris Medical AG, and PregLem, where strategic actions led to acquisitions and an IPO on NASDAQ. Additionally, Sven served as Chairman of the Board at Aimago SA, which was acquired by Novadaq Technologies Inc. in 2014, and held a position as a Board Member at Epiontis GmbH until its acquisition by Precision Medicine Group in 2017. Prior to these roles, Sven worked as an Equity Analyst at UBS from 2001 to 2008.